Vigil Neuroscience, Inc.
VIGL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.25 | 0.07 | -0.03 | 0.19 |
| FCF Yield | -5.43% | -29.49% | -25.62% | 3.12% |
| EV / EBITDA | -12.78 | -1.93 | -1.79 | -5.17 |
| Quality | ||||
| ROIC | -50.17% | -30.16% | -29.69% | -20.32% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 1.07 | 0.76 | -0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 767,343.03% | 767,343.03% | 767,343.03% | 1,245,806.61% |
| Free Cash Flow Growth | 15.01% | -33.28% | -521.79% | 127.74% |
| Safety | ||||
| Net Debt / EBITDA | 1.05 | 1.75 | 1.04 | 1.54 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,872.58 | -664.05 | -678.95 |